This paradigm shift has expanded our vision of depressive disorders as disorders of neuroplasticity rather then simply dysfunctions in monoamine neurotransmitter programs. Furthermore, during the lookup to discover or acquire agents whose mechanism of motion mirrors ketamine’s but will not be connected with its side effects or hazard of abuse has